---
title: "Zylox-Tonbridge Details Valuation Basis for Remaining Stake in Vascular Device Platform"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286568792.md"
description: "Zylox-Tonbridge Medical Technology Co., Ltd. has detailed the valuation basis for acquiring the remaining equity in a European vascular device maker, following an option to buy an additional 11% stake. This move aims to enhance its overseas vascular business and integrate with its sales network. The acquisition reflects the target's improving financials and anticipated growth in market coverage. Analysts rate the stock as a Buy with a target price of HK$28.00."
datetime: "2026-05-15T12:39:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286568792.md)
  - [en](https://longbridge.com/en/news/286568792.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286568792.md)
---

# Zylox-Tonbridge Details Valuation Basis for Remaining Stake in Vascular Device Platform

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( (HK:2190) ) has issued an update.

Zylox-Tonbridge Medical Technology has detailed the valuation basis for its staged acquisition of the remaining equity in a European vascular device maker, after exercising an option to buy an additional 11% stake in March 2026. The company expects this platform to bolster its overseas vascular business through control of brand, intellectual property and distribution, as well as closer integration with its existing sales network.

The consideration for the 11% stake was set after arm’s length talks, referencing the target’s improving financials, including a sharp narrowing of net loss in 2025 and a solid capital position, alongside its advanced positioning in the global peripheral venous stenting market. Pricing for the further acquisition planned for the first half of 2028 also reflects anticipated growth in market coverage, an expanded product portfolio and R&D-driven synergies, including at least 10 new or upgraded products over three years.

The most recent analyst rating on (HK:2190) stock is a Buy with a HK$28.00 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.

**More about Zylox-Tonbridge Medical Technology Co., Ltd. Class H**

Zylox-Tonbridge Medical Technology Co., Ltd. is a China-based medical technology company focused on vascular interventional devices, with a particular emphasis on peripheral venous stenting products. The group uses the target company as its overseas vascular products platform, leveraging its comprehensive portfolio and strong global brand to expand international market reach and strengthen its sales and distribution network.

**Average Trading Volume:** 733,965

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$7.63B

### Related Stocks

- [02190.HK](https://longbridge.com/en/quote/02190.HK.md)

## Related News & Research

- [Zylox-Tonbridge Shareholders Approve All Proposals at 2025 AGM](https://longbridge.com/en/news/286273279.md)
- [Hong Kong considers new offshore yuan venture fund for tech, emerging industries](https://longbridge.com/en/news/288163110.md)
- [IPL 2026 exposed the auction bubble: Franchises paid for names, bargain picks delivered real value](https://longbridge.com/en/news/288235426.md)
- [SEALCOIN - BitMart Listing - 29 May 2026](https://longbridge.com/en/news/288121540.md)
- [HSBC's HDSU delivers scalable, bank-grade settlement across multiple payment rails](https://longbridge.com/en/news/288300719.md)